Table 3.
Pathway Prediction with Enrichr
| Term | Overlap | Adjusted P-value |
Odds Ratio | Combined Score | Genes |
|---|---|---|---|---|---|
| Lung fibrosis (WP3632) | 3/61 | 7.70E−04 | 89.42 | 1103.35 | CCL5; HGF; CXCL2 |
| Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling (WP3675) | 2/31 | 1.12E−02 | 117.30 | 1052.57 | IGFBP5; IGFBP3 |
| Chemokine signaling pathway (WP2292) | 3/190 | 7.72E−03 | 28.71 | 256.52 | CCL22; CCL5; CXCL2 |
| Spinal cord injury (WP2432) | 2/99 | 5.70E−02 | 36.73 | 244.21 | CXCL2; ICAM1 |
| Myometrial relaxation and contraction pathways (WP385) | 2/153 | 1.08E−01 | 23.77 | 137.63 | IGFBP5; IGFBP3 |
| PluriNetWork (WP1763) | 2/292 | 3.14E−01 | 12.45 | 56.49 | IGFBP3; ICAM1 |
| EBV LMP1 signaling (WP1243) | 1/22 | 3.03E−01 | 82.64 | 365.27 | CCL5 |
| Type II interferon signaling (IFNG) (WP1253) | 1/34 | 4.08E−01 | 53.48 | 213.23 | ICAM1 |
| Signaling of hepatocyte growth factor receptor (WP193) | 1/34 | 3.63E−01 | 53.48 | 213.23 | HGF |
| p53 signaling (WP2902) | 1/67 | 6.38E−01 | 27.14 | 90.02 | IGFBP3 |
| IL-5 signaling pathway (WP151) | 1/69 | 5.97E−01 | 26.35 | 86.65 | ICAM1 |
| IL-2 signaling pathway (WP450) | 1/76 | 6.02E−01 | 23.92 | 76.40 | ICAM1 |
| Delta–notch signaling pathway (WP265) | 1/83 | 6.06E−01 | 21.91 | 68.07 | CCN3 |
| Focal adhesion (WP85) | 1/185 | 1.00E+00 | 9.83 | 22.91 | HGF |
| Focal adhesion–PI3K–Akt–mTOR-signaling pathway (WP2841) | 1/324 | 1.00E+00 | 5.61 | 10.13 | HGF |